Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system

Cancer Research

Volumn 74, Issue 21, 2014, Pages 6260-6270

  Xu, Xin ^a   Hegazy, Wael A H ^b,d   Guo, Linjie ^a   Gao, Xiuhua ^a   Courtney, Amy N ^a   Kurbanov, Suhrab ^a   Liu, Daofeng ^a   Tian, Gengwen ^a   Manuel, Edwin R ^c   Diamond, Don J ^c   Hensel, Michael ^b   Metelitsa, Leonid S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OSNABRÜCK   (Germany)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; INTERLEUKIN 12; SURVIVIN; TUMOR ANTIGEN; BACTERIAL PROTEIN; LIVE VACCINE; MEMBRANE PROTEIN; SPI-2 PROTEIN, SALMONELLA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; COLON CARCINOMA; CONTROLLED STUDY; CYTOSOL; FEMALE; GENE LOCUS; IMMUNOGENICITY; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MOUSE; NONHUMAN; PATHOGENICITY ISLAND; PROMOTER REGION; REGULATORY T LYMPHOCYTE; SALMONELLA; TUMOR LOCALIZATION; TUMOR REGRESSION; TYPE III SECRETION SYSTEM; ANIMAL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; NATURAL KILLER T CELL; NEOPLASMS; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; BACTERIAL PROTEINS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; MEMBRANE PROTEINS; MICE; NATURAL KILLER T-CELLS; NEOPLASMS; SALMONELLA TYPHIMURIUM; VACCINES, ATTENUATED;

EID: 84909595148     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1169     Document Type: Article

References (36)

1. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011;239:27-44.
2. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol 2006;208:290-8.
3. Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 2003;101:649-54.
4. Gentschev I, Dietrich G, Spreng S, Kolb-Maurer A, Brinkmann V, Grode L, et al. Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine 2001;19:2621-8.
5. Levine MM. Typhoid vaccines ready for implementation. N Engl J Med 2009;361:403-5.
6. Xiong G, Husseiny MI, Song L, Erdreich-Epstein A, Shackleford GM, Seeger RC, et al. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer 2010;126:2622-34.
7. Manuel ER, Blache CA, Paquette R, Kaltcheva TI, Ishizaki H, Ellenhorn JD, et al. Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res 2011;71: 4183-91.
8. Hegazy WA, Xu X, Metelitsa L, Hensel M. Evaluation of Salmonella enterica type III secretion system effector proteins as carriers for heterologous vaccine antigens. Infect Immun 2012;80: 1193-202.
9. Marlovits TC, Kubori T, Sukhan A, Thomas DR, Galan JE, Unger VM. Structural insights into the assembly of the type III secretion needle complex. Science 2004;306:1040-2.
10. Hensel M, Shea JE, Gleeson C, Jones MD, Dalton E, Holden DW. Simultaneous identification of bacterial virulence genes by negative selection. Science 1995;269:400-3.
11. Hensel M. Salmonella pathogenicity island 2. Mol Microbiol 2000;36: 1015-23.
12. Abrahams GL, Hensel M. Manipulating cellular transport and immune responses: dynamic interactions between intracellular Salmonella enterica and its host cells. Cell Microbiol 2006;8: 728-37.
13. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20.
14. Swann JB, Coquet JM, Smyth MJ, Godfrey DI. CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol 2007;314: 293-323.
15. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariantNKTcells in vaccination strategies. Nat Rev Immunol 2009;9:28-38.
16. Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong CH, et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A 2010;107:13010-5.
17. Xu X, Husseiny MI, Goldwich A, Hensel M. Efficacy of intracellular activated promoters for generation of Salmonella-based vaccines. Infect Immun 2010;78:4828-38.
18. Anguille S, Smits EL, Lion E, van T V, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014;15:e257-67.
19. +/regulatory T cell ratio are associatedwith favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
20. +/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008; 14:2028-35.
21. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73: 3591-603.
22. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003;4:548-56.
23. Blache CA, Manuel ER, Kaltcheva TI, Wong AN, Ellenhorn JD, Blazar BR, et al. Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res 2012;72:6447-56.
24. Manuel ER, Diamond DJ. A road less traveled paved by IDO silencing: Harnessing the antitumor activity of neutrophils. Oncoimmunology 2013;2:e23322.
25. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985;315:672-6.
26. Zhang R, Zhang H, Zhu W, Pardee AB, Coffey RJ Jr, Liang P. Mob-1, a Ras target gene, is overexpressed in colorectal cancer. Oncogene 1997;14:1607-10.
27. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007;67:3396-405.
28. Redjimi N, Raffin C, Raimbaud I, Pignon P, Matsuzaki J, Odunsi K, et al. CXCR3 +T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res 2012;72: 4351-60.
29. Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli S, et al. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci U S A 2009;106:3330-5.
30. Metelitsa LS. Anti-tumor potential of type-I NKT cells against CD1dpositive and CD1d-negative tumors in humans. Clin Immunol 2011;140:119-29.
31. Padte NN, Li X, Tsuji M, Vasan S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol 2011;140:142-51.
32. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007;204: 2641-53.
33. + T cell induction. J Immunol 2013;190:5609-19.
34. Kronenberg M. Toward an Understanding of NKT Cell Biology: Progress and Paradoxes. Annu Rev Immunol 2005;23:877-900.
35. Charalambous A, Oks M, Nchinda G, Yamazaki S, Steinman RM. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J Immunol 2006;177:8410-21.
36. Yu P, Spiotto MT, Lee Y, Schreiber H, Fu YX. Complementary role of CD4+ T cells and secondary lymphoid tissues for crosspresentation of tumor antigen to CD8 +T cells. J Exp Med 2003; 197:985-95.